Symbols / AZN
AZN Chart
About
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the Americas, rest of Europe, Asia, Africa, and Australasia. It has a strategic agreement with Tempus and Pathos to develop the largest multimodal foundation model in oncology; and a strategic research collaboration with CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Drug Manufacturers - Gen | Market Cap | 318.82B |
| Enterprise Value | 344.47B | Income | 10.23B | Sales | 58.74B |
| Book/sh | 31.38 | Cash/sh | 3.70 | Dividend Yield | 155.00% |
| Payout | 47.91% | Employees | — | IPO | — |
| P/E | 31.40 | Forward P/E | 34.69 | PEG | — |
| P/S | 5.43 | P/B | 6.55 | P/C | — |
| EV/EBITDA | 17.69 | EV/Sales | 5.86 | Quick Ratio | 0.72 |
| Current Ratio | 0.94 | Debt/Eq | 60.97 | LT Debt/Eq | — |
| EPS (ttm) | 6.55 | EPS next Y | 5.93 | EPS Growth | 53.90% |
| Revenue Growth | 4.10% | Earnings | 2026-04-29 | ROA | 7.88% |
| ROE | 22.84% | ROIC | — | Gross Margin | 81.90% |
| Oper. Margin | 18.05% | Profit Margin | 17.41% | Shs Outstand | 1.55B |
| Shs Float | 1.54B | Short Float | — | Short Ratio | — |
| Short Interest | — | 52W High | 212.71 | 52W Low | 122.26 |
| Beta | 0.19 | Avg Volume | 655.77K | Volume | 599.34K |
| Target Price | $164.66 | Recom | Buy | Prev Close | $206.61 |
| Price | $205.65 | Change | -0.46% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$164.66
Mean price target
2. Current target
$205.65
Latest analyst target
3. DCF / Fair value
$78.08
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$205.65
Low
$98.00
High
$232.00
Mean
$164.66
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-02-13 | up | UBS | Neutral → Buy | — |
| 2024-11-20 | up | UBS | Sell → Neutral | — |
| 2024-09-11 | up | Erste Group | Hold → Buy | — |
| 2024-08-12 | main | TD Cowen | Buy → Buy | $95 |
| 2024-05-30 | main | Argus Research | Buy → Buy | $85 |
| 2024-05-30 | init | Goldman Sachs | — → Buy | $97 |
| 2024-04-26 | main | BMO Capital | Outperform → Outperform | $82 |
| 2024-04-16 | up | Deutsche Bank | Sell → Hold | — |
| 2024-02-12 | main | BMO Capital | Outperform → Outperform | $80 |
| 2024-02-08 | down | Deutsche Bank | Buy → Hold | — |
| 2024-01-23 | init | Morgan Stanley | — → Overweight | $85 |
| 2024-01-03 | down | Jefferies | Buy → Hold | — |
| 2023-09-25 | up | Jefferies | Hold → Buy | $80 |
| 2023-09-08 | down | Erste Group | Buy → Hold | — |
| 2023-08-01 | main | BMO Capital | Outperform → Outperform | $83 |
| 2023-05-26 | main | Argus Research | Buy → Buy | $80 |
| 2023-04-13 | main | Argus Research | — → Buy | $85 |
| 2023-01-05 | init | BMO Capital | — → Outperform | $82 |
| 2022-11-14 | main | SVB Leerink | — → Outperform | $79 |
| 2022-11-11 | main | SVB Leerink | — → Outperform | $78 |
News
RSS: Latest AZN news- AstraZeneca Stock Soared 103% Monday, Holding At High Level. Gets Rating Upgrade. - Investor's Business Daily ue, 03 Feb 2026 08
- AstraZeneca Files 2025 Form 20-F Annual Report with U.S. SEC - TipRanks Wed, 25 Feb 2026 08
- Assessing AstraZeneca (LSE:AZN) Valuation After Strong Recent Share Price Momentum - simplywall.st ue, 24 Feb 2026 23
- ABBV vs. AZN: Which Pharma Stock is the Better Investment Now? - Yahoo Finance ue, 23 Dec 2025 08
- AstraZeneca lists on the NYSE on Monday, ending ADS program - Seeking Alpha Mon, 02 Feb 2026 08
- Understanding the Setup: (AZN) and Scalable Risk - Stock Traders Daily Mon, 23 Feb 2026 09
- Why AstraZeneca PLC (AZN) is One of the Best Immunotherapy Stocks to Buy According to Hedge Funds - Finviz hu, 19 Feb 2026 15
- Breast cancer drug ENHERTU heads for EU review after 53% relapse risk drop - Stock Titan hu, 19 Feb 2026 07
- Woodley Farra Manion Portfolio Management Inc. Lowers Holdings in AstraZeneca PLC $AZN - MarketBeat Fri, 20 Feb 2026 15
- AstraZeneca Shares Start Trading in US After Listing Upgrade - Yahoo Finance Mon, 02 Feb 2026 08
- AstraZeneca Stock (AZN) Hits NYSE — Should US Investors Pay Attention? - TipRanks Mon, 02 Feb 2026 08
- AstraZeneca (NYSE: AZN) begins NYSE trading under harmonised global listing - Stock Titan Mon, 02 Feb 2026 08
- AstraZeneca PLC (LON:AZN) Just Reported Full-Year Earnings: Have Analysts Changed Their Mind On The Stock? - Yahoo Finance hu, 12 Feb 2026 08
- Astrazeneca (AZN) Stock Declines While Market Improves: Some Information for Investors - Yahoo Finance ue, 28 Oct 2025 07
- A Closer Look At AstraZeneca (LSE:AZN) Valuation After Recent Share Price Momentum - Yahoo Finance ue, 17 Feb 2026 10
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 297 | 53622.0 | — | Sold at price 180.55 per share. | Rahman (Nazneen) | — | — | 2025-12-18 00:00:00 | D |
| 1 | 1018521 | nan | — | — | The Capital Group Companies, Inc. | — | — | 2025-12-02 00:00:00 | D |
| 2 | 2750450 | nan | — | — | The Capital Group Companies, Inc. | — | — | 2025-11-13 00:00:00 | D |
| 3 | 249861 | nan | — | — | Soriot (Pascal) | — | — | 2025-11-07 00:00:00 | D |
| 4 | 183466 | nan | — | — | The Capital Group Companies, Inc. | — | — | 2025-08-22 00:00:00 | D |
| 5 | 516203 | nan | — | — | The Capital Group Companies, Inc. | — | — | 2025-08-19 00:00:00 | D |
| 6 | 9563 | 1489628.0 | — | Bought at price 155.77 per share. | Sarin (Aradhana M.D.) | — | — | 2025-08-14 00:00:00 | D |
| 7 | 431237 | nan | — | — | The Capital Group Companies, Inc. | — | — | 2025-08-13 00:00:00 | D |
| 8 | 1281686 | nan | — | — | The Capital Group Companies, Inc. | — | — | 2025-08-08 00:00:00 | D |
| 9 | 8970 | nan | — | — | Soriot (Pascal) | — | — | 2025-05-21 00:00:00 | D |
Financials
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | -66.49M | -140.79M |
| TaxRateForCalcs | 0.17 | 0.19 | 0.14 | 0.19 |
| NormalizedEBITDA | 19.83B | 17.12B | 13.91B | 9.83B |
| TotalUnusualItems | -153.00M | -489.00M | -741.00M | 1.19B |
| TotalUnusualItemsExcludingGoodwill | -153.00M | -489.00M | -741.00M | 1.19B |
| NetIncomeFromContinuingOperationNetMinorityInterest | 10.22B | 7.04B | 5.96B | 3.29B |
| ReconciledDepreciation | 5.73B | 6.69B | 4.93B | 5.25B |
| ReconciledCostOfRevenue | 10.63B | 10.21B | 8.27B | 12.39B |
| EBITDA | 19.83B | 17.12B | 13.42B | 9.09B |
| EBIT | 14.10B | 10.43B | 8.49B | 3.83B |
| NetInterestIncome | -1.33B | -1.28B | -1.29B | -1.25B |
| InterestExpense | 1.69B | 1.74B | 1.59B | 1.33B |
| InterestIncome | 360.00M | 458.00M | 301.00M | 81.00M |
| NormalizedIncome | 10.22B | 7.04B | 6.38B | 3.89B |
| NetIncomeFromContinuingAndDiscontinuedOperation | 10.22B | 7.04B | 5.96B | 3.29B |
| TotalExpenses | 45.00B | 44.07B | 37.09B | 39.84B |
| RentExpenseSupplemental | 377.00M | 301.00M | 268.00M | 262.00M |
| TotalOperatingIncomeAsReported | 13.74B | 10.00B | 8.19B | 3.76B |
| DilutedAverageShares | 1.56B | 1.56B | 1.56B | 1.56B |
| BasicAverageShares | 1.55B | 1.55B | 1.55B | 1.55B |
| DilutedEPS | 6.54 | 4.50 | 3.81 | 2.11 |
| BasicEPS | 6.60 | 4.54 | 3.84 | 2.12 |
| DilutedNIAvailtoComStockholders | 10.22B | 7.04B | 5.96B | 3.29B |
| NetIncomeCommonStockholders | 10.22B | 7.04B | 5.96B | 3.29B |
| OtherunderPreferredStockDividend | 0.00 | 0.00 | 0.00 | 0.00 |
| NetIncome | 10.22B | 7.04B | 5.96B | 3.29B |
| MinorityInterests | -8.00M | -6.00M | -6.00M | -5.00M |
| NetIncomeIncludingNoncontrollingInterests | 10.23B | 7.04B | 5.96B | 3.29B |
| NetIncomeContinuousOperations | 10.23B | 7.04B | 5.96B | 3.29B |
| TaxProvision | 2.17B | 1.65B | 938.00M | -792.00M |
| PretaxIncome | 12.40B | 8.69B | 6.90B | 2.50B |
| SpecialIncomeCharges | -248.00M | -529.00M | -755.00M | 1.20B |
| OtherSpecialCharges | -12.00M | 9.00M | 573.00M | -1.24B |
| ImpairmentOfCapitalAssets | 0.00 | 0.00 | ||
| RestructuringAndMergernAcquisition | 260.00M | 520.00M | 182.00M | 42.00M |
| NetNonOperatingInterestIncomeExpense | -1.33B | -1.28B | -1.29B | -1.25B |
| InterestExpenseNonOperating | 1.69B | 1.74B | 1.59B | 1.33B |
| InterestIncomeNonOperating | 360.00M | 458.00M | 301.00M | 81.00M |
| OperatingIncome | 13.74B | 10.00B | 8.72B | 4.51B |
| OperatingExpense | 34.36B | 33.86B | 28.82B | 27.45B |
| OtherOperatingExpenses | 121.00M | 164.00M | 200.00M | 308.00M |
| DepreciationAndAmortizationInIncomeStatement | 1.00M | |||
| Amortization | 1.00M | |||
| DepreciationIncomeStatement | 0.00 | |||
| ResearchAndDevelopment | 14.23B | 13.58B | 10.94B | 9.76B |
| SellingGeneralAndAdministration | 20.51B | 20.53B | 18.22B | 17.98B |
| SellingAndMarketingExpense | 579.00M | 555.00M | 539.00M | 536.00M |
| GeneralAndAdministrativeExpense | 19.93B | 19.98B | 17.68B | 17.45B |
| GrossProfit | 48.11B | 43.87B | 37.54B | 31.96B |
| CostOfRevenue | 10.63B | 10.21B | 8.27B | 12.39B |
| TotalRevenue | 58.74B | 54.07B | 45.81B | 44.35B |
| OperatingRevenue | 58.74B | 54.07B | 45.81B | 44.35B |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TreasurySharesNumber | 442.34K | 0.00 | 0.00 | 0.00 |
| PreferredSharesNumber | 50.00K | |||
| OrdinarySharesNumber | 1.55B | 1.55B | 1.55B | 1.55B |
| ShareIssued | 1.55B | 1.55B | 1.55B | 1.55B |
| NetDebt | 22.11B | 23.17B | 21.44B | 22.02B |
| TotalDebt | 29.62B | 30.11B | 28.41B | 29.14B |
| TangibleBookValue | -10.42B | -17.42B | -18.99B | -22.09B |
| InvestedCapital | 76.49B | 69.45B | 66.42B | 65.23B |
| WorkingCapital | -1.89B | -2.04B | -5.49B | -3.70B |
| NetTangibleAssets | -10.42B | -17.42B | -18.99B | -22.09B |
| CapitalLeaseObligations | 1.80B | 1.45B | 1.13B | 953.00M |
| CommonStockEquity | 48.67B | 40.79B | 39.14B | 37.04B |
| TotalCapitalization | 73.38B | 67.29B | 61.51B | 60.00B |
| TotalEquityGrossMinorityInterest | 48.72B | 40.87B | 39.17B | 37.06B |
| MinorityInterest | 52.00M | 85.00M | 23.00M | 21.00M |
| StockholdersEquity | 48.67B | 40.79B | 39.14B | 37.04B |
| RetainedEarnings | 10.97B | 3.16B | 1.50B | -574.00M |
| AdditionalPaidInCapital | 35.27B | 35.38B | 35.34B | 35.31B |
| CapitalStock | 388.00M | 388.00M | 388.00M | 387.00M |
| CommonStock | 388.00M | 388.00M | 388.00M | 387.00M |
| TotalLiabilitiesNetMinorityInterest | 65.36B | 63.16B | 61.95B | 59.42B |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 34.74B | 35.30B | 31.41B | 33.13B |
| DerivativeProductLiabilities | 0.00 | 115.00M | 38.00M | 943.00M |
| NonCurrentPensionAndOtherPostretirementBenefitPlans | 1.10B | 1.33B | 1.52B | 1.17B |
| NonCurrentAccruedExpenses | 65.00M | 36.00M | 37.00M | 25.00M |
| TradeandOtherPayablesNonCurrent | 3.08B | 1.94B | 2.62B | 3.44B |
| NonCurrentDeferredRevenue | 0.00 | 7.00M | 14.00M | 26.00M |
| NonCurrentDeferredTaxesLiabilities | 3.50B | 3.31B | 2.84B | 2.94B |
| LongTermDebtAndCapitalLeaseObligation | 26.14B | 27.62B | 23.22B | 23.69B |
| LongTermCapitalLeaseObligation | 1.42B | 1.11B | 857.00M | 725.00M |
| LongTermDebt | 24.71B | 26.51B | 22.36B | 22.96B |
| LongTermProvisions | 918.00M | 921.00M | 1.13B | 896.00M |
| CurrentLiabilities | 30.62B | 27.87B | 30.54B | 26.29B |
| CurrentDebtAndCapitalLeaseObligation | 3.49B | 2.50B | 5.18B | 5.45B |
| CurrentCapitalLeaseObligation | 382.00M | 339.00M | 271.00M | 228.00M |
| CurrentDebt | 3.10B | 2.16B | 4.91B | 5.22B |
| CurrentProvisions | 686.00M | 1.27B | 1.03B | 722.00M |
| Payables | 26.36B | 8.06B | 7.62B | 5.84B |
| OtherPayable | 2.61B | 2.28B | 1.93B | 1.66B |
| TotalTaxPayable | 1.08B | 1.81B | 2.08B | 1.36B |
| AccountsPayable | 25.28B | 3.64B | 3.27B | 2.55B |
| TotalAssets | 114.07B | 104.03B | 101.12B | 96.48B |
| TotalNonCurrentAssets | 85.35B | 78.21B | 76.06B | 73.89B |
| DefinedPensionBenefit | 99.00M | 92.00M | 90.00M | 0.00 |
| NonCurrentPrepaidAssets | 356.00M | 274.00M | 243.00M | 391.00M |
| NonCurrentDeferredTaxesAssets | 5.82B | 5.35B | 4.72B | 3.26B |
| FinancialAssets | 498.00M | 182.00M | 228.00M | 74.00M |
| OtherInvestments | 2.22B | 1.63B | 1.53B | |
| InvestmentinFinancialAssets | 1.63B | 1.53B | 1.07B | 1.17B |
| AvailableForSaleSecurities | 1.63B | 1.53B | 1.06B | 1.17B |
| FinancialAssetsDesignatedasFairValueThroughProfitorLossTotal | 0.00 | 0.00 | 10.00M | 0.00 |
| LongTermEquityInvestment | 302.00M | 268.00M | 147.00M | 76.00M |
| GoodwillAndOtherIntangibleAssets | 59.09B | 58.20B | 58.14B | 59.13B |
| OtherIntangibleAssets | 37.85B | 37.18B | 38.09B | 39.31B |
| Goodwill | 21.24B | 21.02B | 20.05B | 19.82B |
| NetPPE | 14.70B | 11.65B | 10.50B | 9.45B |
| AccumulatedDepreciation | -8.88B | -8.60B | -7.74B | -8.32B |
| GrossPPE | 14.70B | 20.52B | 19.10B | 17.19B |
| ConstructionInProgress | 2.79B | 2.04B | 2.65B | 2.73B |
| OtherProperties | 14.70B | 47.00M | 36.00M | 32.00M |
| MachineryFurnitureEquipment | 9.52B | 9.20B | 7.88B | 8.22B |
| BuildingsAndImprovements | 1.59B | 1.35B | 1.18B | 1.13B |
| LandAndImprovements | 6.58B | 6.47B | 5.44B | 6.38B |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 28.72B | 25.83B | 25.05B | 22.59B |
| OtherCurrentAssets | 105.00M | |||
| HedgingAssetsCurrent | 90.00M | 54.00M | 116.00M | 87.00M |
| AssetsHeldForSaleCurrent | 0.00 | 0.00 | 150.00M | 368.00M |
| RestrictedCash | 129.00M | 102.00M | 162.00M | 0.00 |
| PrepaidAssets | 1.74B | 1.62B | 1.33B | 1.51B |
| Inventory | 6.56B | 5.29B | 5.42B | 4.70B |
| FinishedGoods | 1.52B | 1.57B | 1.41B | 2.01B |
| WorkInProcess | 2.28B | 2.33B | 1.86B | 5.22B |
| RawMaterials | 1.49B | 1.53B | 1.42B | 1.75B |
| OtherReceivables | 2.93B | 2.10B | 1.98B | 2.10B |
| TaxesReceivable | 1.16B | 1.86B | 1.43B | 731.00M |
| AccountsReceivable | 15.18B | 8.30B | 8.41B | 7.21B |
| AllowanceForDoubtfulAccountsReceivable | -33.00M | -45.00M | -59.00M | -23.00M |
| GrossAccountsReceivable | 8.34B | 8.45B | 7.27B | 6.05B |
| CashCashEquivalentsAndShortTermInvestments | 5.74B | 5.53B | 5.86B | 6.24B |
| OtherShortTermInvestments | 30.00M | 37.00M | 20.00M | 77.00M |
| CashAndCashEquivalents | 5.71B | 5.49B | 5.84B | 6.17B |
| CashEquivalents | 4.27B | 4.51B | 4.75B | 4.87B |
| CashFinancial | 1.22B | 1.32B | 1.41B | 1.46B |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| FreeCashFlow | 8.67B | 7.28B | 6.57B | 7.24B |
| RepaymentOfDebt | -2.03B | -4.65B | -4.94B | -1.27B |
| IssuanceOfDebt | 15.00M | 6.49B | 3.82B | 0.00 |
| IssuanceOfCapitalStock | -481.00M | -43.00M | 33.00M | 29.00M |
| CapitalExpenditure | -5.91B | -4.59B | -3.78B | -2.57B |
| EndCashPosition | 5.70B | 5.43B | 5.64B | 5.98B |
| BeginningCashPosition | 5.43B | 5.64B | 5.98B | 6.04B |
| EffectOfExchangeRateChanges | 46.00M | -93.00M | -60.00M | -80.00M |
| ChangesInCash | 223.00M | -115.00M | -286.00M | 25.00M |
| FinancingCashFlow | -7.54B | -4.00B | -6.57B | -6.82B |
| NetOtherFinancingCharges | -70.00M | -817.00M | -886.00M | -1.05B |
| CashDividendsPaid | -4.97B | -4.63B | -4.48B | -4.36B |
| CommonStockDividendPaid | -4.97B | -4.63B | -4.48B | -4.36B |
| NetCommonStockIssuance | -481.00M | -43.00M | 33.00M | 29.00M |
| CommonStockIssuance | -481.00M | -43.00M | 33.00M | 29.00M |
| NetIssuancePaymentsOfDebt | -1.65B | 1.81B | -965.00M | -1.20B |
| NetShortTermDebtIssuance | 364.00M | -31.00M | 161.00M | 74.00M |
| NetLongTermDebtIssuance | -2.01B | 1.84B | -1.13B | -1.27B |
| LongTermDebtPayments | -2.03B | -4.65B | -4.94B | -1.27B |
| LongTermDebtIssuance | 15.00M | 6.49B | 3.82B | 0.00 |
| InvestingCashFlow | -6.81B | -7.98B | -4.06B | -2.96B |
| NetOtherInvestingChanges | 190.00M | 20.00M | ||
| InterestReceivedCFI | 286.00M | 343.00M | 287.00M | 60.00M |
| NetInvestmentPurchaseAndSale | -98.00M | 12.00M | -7.00M | -117.00M |
| SaleOfInvestment | 131.00M | 108.00M | 129.00M | 42.00M |
| PurchaseOfInvestment | -229.00M | -96.00M | -136.00M | -159.00M |
| NetBusinessPurchaseAndSale | -1.24B | -3.93B | -1.18B | -1.06B |
| SaleOfBusiness | 0.00 | 13.00M | 0.00 | 0.00 |
| PurchaseOfBusiness | -1.24B | -3.94B | -1.18B | -1.06B |
| NetIntangiblesPurchaseAndSale | -2.96B | -2.54B | -2.13B | -1.03B |
| SaleOfIntangibles | 136.00M | 123.00M | 291.00M | 447.00M |
| PurchaseOfIntangibles | -3.10B | -2.66B | -2.42B | -1.48B |
| NetPPEPurchaseAndSale | -2.80B | -1.87B | -1.23B | -809.00M |
| SaleOfPPE | 13.00M | 55.00M | 132.00M | 282.00M |
| PurchaseOfPPE | -2.81B | -1.92B | -1.36B | -1.09B |
| OperatingCashFlow | 14.57B | 11.86B | 10.35B | 9.81B |
| TaxesRefundPaid | -2.85B | -2.75B | -2.37B | -1.62B |
| InterestPaidCFO | -1.32B | -1.31B | -1.08B | -849.00M |
| ChangeInWorkingCapital | -1.14B | -893.00M | 300.00M | 3.76B |
| ChangeInPayable | 862.00M | 2.39B | 1.17B | 1.41B |
| ChangeInInventory | -131.00M | -669.00M | 3.94B | 1.58B |
| ChangeInReceivables | -1.62B | -1.43B | -1.35B | -961.00M |
| OtherNonCashItems | 1.90B | 1.47B | 1.45B | 639.00M |
| DepreciationAndAmortization | 5.73B | 6.69B | 4.93B | 5.25B |
| AmortizationCashFlow | 3.92B | 3.93B | 4.16B | 3.14B |
| Depreciation | 5.73B | 6.69B | 1.01B | 1.10B |
| GainLossOnInvestmentSecurities | -95.00M | -40.00M | -14.00M | 4.00M |
| NetForeignCurrencyExchangeGainLoss | 42.00M | 34.00M | 16.00M | 20.00M |
| GainLossOnSaleOfPPE | -168.00M | -64.00M | -251.00M | -104.00M |
| GainLossOnSaleOfBusiness | 0.00 | 0.00 | -776.00M | |
| NetIncomeFromContinuingOperations | 12.40B | 8.69B | 6.90B | 2.50B |
Public Trades for AZN
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|